u/Jazzlike_Bet_6023

I have a 25 year career in pharmaceuticals, with the last 10 inside commercial leadership and strategy in nuclear medicine and complex therapies. I moved to Amsterdam six months ago with my family, because my wife had an opportunity that she couldn’t pass up and things have been cold ever since. I was definitely someone with an abundance of options in the states, so while I assumed that there would be an adjustment phase, I’m left feeling like I’m running on black ice. Would love some suggestions.

* I wrote this observation based on a trend that’s been plaguing our market and eroding the fabric of complex therapeutics. I am a 25 year pharmaceutical veteran, with the last ten years in radiopharmaceutical commercial strategy and leadership.

There is a particular kind of meeting that happens inside nearly every large company, usually in a room with windows that look down on a campus built on the back of past success. A number goes up on a screen. The number didn’t come from the market. It came from a consulting deck, built by people who’d spent perhaps three weeks with the business, and from what Wall Street already expected after last quarter’s promise. The number is not technically a description of anything. It’s a guess about what would be well received, dressed in the language of benchmarks and analysis, and everyone in the room nods at it as though it were a fact about the world.

Somewhere else in the building, usually several floors and several org chart boxes away from that room, are people who could have told them the number was fiction before it ever reached a slide. They are the ones who spend their days closest to the actual market, who know its adoption curve, its seasonality, the specific and unglamorous ways it refuses to behave like the company’s core business. Ask any one of them to react to the projection honestly, and the number wouldn’t survive the conversation. Not because these people lack ambition, and not because they’d want to talk anyone out of an aggressive target. It would fail because the reality of the market, plainly described, makes the fiction impossible to keep believing.

So, that conversation never happens. Not because it’s impossible to arrange, a meeting can always be arranged, but because having it would require someone senior to admit, before a single dollar has changed hands, that the number they’re about to promise to public markets might be wrong. Arrogance closes that door as often as ignorance, and it’s rarely obvious which one is operating at any given time. The guess goes to the board un-stress-tested, the board takes it to Wall Street, and the moment it becomes a public commitment, the company stops being in the business of understanding its market and starts being in the business of defending a sentence it said out loud.

This is the part of corporate life that gets the least attention and does the most damage: not the fictional number itself, and not even the refusal to check it, but what happens next, once the number is public and wrong. From that point forward, every decision the organization makes is graded against a single, unstated question that has nothing to do with the market: how do we make it look like we knew what we were talking about? What follows is not one bad call. It’s a cascade of them, each one designed to protect the last, until the thing being protected is no longer the target but the illusion that the target was ever reasonable.

Consider a company that has just acquired, or built internally, a specialized business unit: a niche product, an emerging technology, a market segment that behaves nothing like the company’s core business. The people running this unit are the ones who could have corrected the number before it went public. They weren’t asked in a formal sense. The projection reaches them only after the fact, as a target already promised to people outside the building, and their job is no longer to describe the market honestly. It’s to close a gap between what was said and what’s true, using whatever means the org chart allows them.

The quarter comes in. It’s positive. It’s real growth, real revenue, a real product finding real customers. It’s also, inevitably, short of the number on the screen in the room. A company with an honest relationship to its own forecasting would treat the miss as information: the model was wrong, the market is different than we assumed, let’s learn something. Almost no company does this. Admitting the forecast was wrong means admitting that the people who made it, who are often the most senior people in the building, misjudged something basic. So the organization reaches for the cheaper alternative. It decides the forecast was right and the execution was wrong.

This is the hinge the entire story turns on: a market problem gets reclassified as a leadership problem, because a leadership problem is fixable in a way that doesn’t require anyone upstairs to have been mistaken.

Once the miss becomes a leadership story, the response is fast and familiar. The niche unit’s leader, who has spent months absorbing pressure for a number he never should have been held to, starts to feel the walls close in. He does the natural thing. He tries to conform to what the parent company wants, tries to speak its language, adopt its cadence. What comes out of that effort is never quite right. It can’t be. He is translating a business that doesn’t map cleanly onto the company’s usual vocabulary, and the translation reads, to the people evaluating him, as weakness: a leader losing command of his own room.

So they replace him. They don’t promote a stranger. They reach for someone familiar, usually from a more conventional part of the business, someone whose success was built in a market that behaves the way the company’s models assume all markets behave. This person is, by every metric the company knows how to measure, a safe choice. What nobody in that boardroom seems to register is that the track record was earned in a different country, under different weather, and doesn’t necessarily travel.

The new leader arrives with real credibility and no relevant expertise, and this combination produces a specific, almost clinical form of vulnerability. He is surrounded by people who understand his new business better than he does, and everyone in the room knows it, including him. He has two paths available: spend his political capital admitting what he doesn’t know, or protect the version of himself that got him the job in the first place. Almost nobody, placed in that position, chooses the humbling path. Most choose protection. And protection, in a business unit staffed with people who can see through you, means getting rid of the people who can see through you.

This is where the story arrives at what I’ve called Hostile Nepotism, though by this point the name almost undersells what’s happening. It isn’t simple favoritism, a friend given a soft landing. It’s a defense mechanism with a body count. The specialists who could expose the new leader’s gaps get reframed as difficult, as lacking perspective, as not quite fitting the culture. The people who replace them are chosen for a single, unstated qualification: they know less than the leader does. The unit’s actual expertise walks out the door in stages, and nobody files a report that says so, because there is no line item for institutional memory.

None of it works, not really, though it can take years to become undeniable. Growth stalls. The people who might have fixed it are gone or have stopped offering opinions that go unheard. Eventually the numbers force another reckoning, and the organization does the only thing it has ever learned how to do when a forecast fails: it looks for a new leader. Someone familiar. Someone safe. The cycle does not end because nobody in the building has ever been forced to ask the one question that would end it, which is not “who should run this unit” but “why did we promise Wall Street something we didn’t understand well enough to promise.”

That question never gets asked, because asking it means someone very senior has to say, out loud, that the mistake was made before anyone was ever hired or fired. Everything after that, the squeeze, the ouster, the new leader’s fear, the purge of the experts who could have saved him, is just the bill for that first, invisible decision, arriving in installments, to people who had no idea they were the ones who’d be paying it.

And the debt doesn’t clear when one leader falls. Each turn of the cycle spends down something the company can’t easily rebuild: the trust of the people who still remember how the unit was supposed to work, the culture that made the work good in the first place, the difference between a promising business and a cautionary one told at other companies as a warning. None of it was destroyed by a single bad actor. It was spent, in small installments, by an organization that never once went back to ask whether the original number had ever been true.